Unknown

未知

• 批准号: 429133
• 负责人: Yu Ivan P
• 金额: $ 1.27万
• 依托单位: University of British Columbia
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2019
• 资助国家: 加拿大
• 起止时间: 2019-12-01 至 2020-12-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=429133&lang=en
• 关键词: Androgen Receptor; Androgen Receptor Variant 7; Biotin-Labelling; Co-Factors; In-Vitro; Interactomes; Mass Spectrometry; Prostate Cancer; Split-Proteins

"Prostate cancer (PCa) is the second-leading cause of cancer-related deaths in men, where inhibition of androgen receptor (AR) is the standard-of-care to treat recurrent or metastatic PCa. While this is initially effective, resistance often develops, resu

“前列腺癌（PCa）是男性癌症相关死亡的第二大原因，其中抑制雄激素受体（AR）是治疗复发性或转移性前列腺癌的标准治疗方法。虽然这在最初是有效的，但往往会产生耐药性，